Our previous study showed that serum containing FYD could reverse the tumorigenicity of BMSCs in the glioma microenvironment by inhibiting the telomerase activity of BMSCs, increasing the expression of p53, and inducing apoptosis in vivo [27, 46]. The gene discussed is TP53; the disease is glioma.